You’ve probably heard it called “GLP-3.” Here’s what retatrutide actually is, what the trial data shows, and why you can’t get it yet.
What Is Retatrutide?
Retatrutide is an investigational drug that activates three hormone receptors, GLP-1, GIP, and glucagon, at the same time, which is why some people call it “GLP-3” even though that’s not an official term. Eli Lilly is studying it for obesity, type 2 diabetes, and fatty liver disease, and the FDA has not approved it yet.
Eli Lilly developed retatrutide, research code LY3437943, as a once-weekly injection. It belongs to a broader category of peptide therapy drugs that use lab-made versions of the body’s own signaling molecules to change how it manages hunger, blood sugar, and fat storage.
Researchers are studying retatrutide for three conditions: obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease, more commonly known as fatty liver disease. Early trial data suggests it could outperform currently approved options on all three fronts. That word, “could,” matters, since the drug is still years from approval.
Is “GLP-3” the Same Thing as Retatrutide?
No. There’s no GLP-3 receptor, no GLP-3 hormone, and no such thing as a “GLP-3 drug class” in pharmacology. “GLP-3” is an informal nickname that spread in 2026 after outlets including Fox News, Scientific American, and MedicalXpress used it to describe retatrutide in headlines about its Phase 3 trial results.
The logic behind the nickname is simple. Semaglutide activates one receptor, GLP-1. Tirzepatide activates two, GLP-1 and GIP. Retatrutide activates three: GLP-1, GIP, and glucagon. Someone started counting, and “GLP-3” stuck. It’s a useful shorthand for what the drug does, but it isn’t a real classification, and no regulatory body recognizes it.
GLP-1 vs. GLP-2 vs. “GLP-3”: What’s Actually Different
GLP-2 adds to the confusion because it sounds like part of the same family, but it belongs to a completely separate system. GLP-2 is a real, distinct gut hormone that helps the intestines absorb nutrients and repair their lining. It has no role in appetite or weight regulation, and retatrutide doesn’t interact with it at all. GLP-1, GIP, and glucagon are the only three receptors involved in retatrutide’s mechanism. GLP-2 sits outside that picture entirely.
How Retatrutide Works
Retatrutide’s three receptors each handle a different part of the process. GLP-1 slows digestion and signals fullness to the brain. GIP improves how the body releases and uses insulin after eating. Glucagon, usually associated with raising blood sugar, also increases how many calories the body burns at rest and helps the liver clear stored fat.
Activating all three receptors at once is what separates retatrutide from single- or dual-receptor drugs. Each one contributes a different piece of the metabolic picture, and combining them produces effects that no single receptor manages on its own. That’s the working hypothesis behind triple-agonist research, and it’s what Lilly’s TRIUMPH trials are built to confirm.
What the Research Shows: Retatrutide Benefits
Weight Loss in Clinical Trials
In Lilly’s Phase 2 trial, participants taking the highest dose, 12mg, lost an average of 24.2% of their body weight over 48 weeks, the largest reduction recorded for any GLP-1 class medication at that point. Phase 3 TRIUMPH-1 data released in May 2026 went further: participants on 12mg lost an average of 28.3% of their body weight over 80 weeks, and nearly half lost 30% or more.
These are results from specific trial populations at specific doses, not a promise of what any individual will experience. Results vary by dose, duration, and starting weight, which is exactly why a personalized protocol built on real lab work matters more than a headline percentage.
Liver Fat and Metabolic Improvements
Trial participants also saw meaningful drops in liver fat, along with improvements in blood pressure, triglycerides, and A1c, a marker of long-term blood sugar control. That combination is why Lilly added a dedicated fatty liver disease trial to the Phase 3 program, and why retatrutide gets discussed as a metabolic drug rather than a weight-loss drug alone.
Retatrutide Side Effects
Like other drugs in this category, retatrutide’s most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These symptoms show up most often when starting treatment or stepping up a dose, and they tend to ease as the body adjusts.
About 10% of trial participants stopped treatment because of side effects, a rate comparable to tirzepatide and semaglutide. Because retatrutide is still investigational, researchers don’t yet have the years of real-world safety data that exist for approved GLP-1 drugs. That gap closes as the TRIUMPH trials continue, not before.
Retatrutide vs. Semaglutide and Tirzepatide
Semaglutide, tirzepatide, and retatrutide represent three generations of the same approach, each adding one more receptor than the last.
Semaglutide (GLP-1 Only)
Semaglutide, sold as Ozempic and Wegovy, activates only the GLP-1 receptor. It’s FDA-approved, prescribable today, and produced roughly 15% average weight loss in its pivotal trials.
Tirzepatide (GLP-1 + GIP)
Tirzepatide, sold as Mounjaro and Zepbound, adds the GIP receptor to GLP-1. It’s also FDA-approved and available now, with roughly 21% average weight loss in its pivotal trials, currently the benchmark for this drug class.
Retatrutide (GLP-1 + GIP + Glucagon)
Retatrutide adds a third receptor, glucagon, on top of both. Trial data puts its weight loss results ahead of both approved drugs, but it isn’t approved and isn’t prescribable. It won’t be available through Dynamis’s GLP-1 weight-loss protocols, or through any other provider, until that changes.
Is Retatrutide FDA-Approved, and What Does Safe Access Look Like?
No, not yet. Retatrutide is currently in Phase 3 clinical trials under Lilly’s TRIUMPH program. If trials continue to go well, Lilly is expected to file for FDA approval later in 2026, with a review that typically takes 10 to 12 months after that. None of that timeline is official, and delays are common in drug development.
Why Self-Injecting Retatrutide Right Now Isn’t Safe
Because retatrutide isn’t approved, it isn’t available at a pharmacy and isn’t covered by insurance. That hasn’t stopped a black market from forming. Reporting from Futurism and the Partnership for Safe Medicines has documented people buying unregulated “research peptide” retatrutide online and injecting it without medical supervision, verified dosing, or quality testing.
That supply chain carries real risk: contamination, incorrect concentration, and no clinician reviewing your health history or watching for complications. Public health researchers have said plainly that a clinical trial is currently the only way to access retatrutide with verified quality and medical oversight.
Dynamis doesn’t offer retatrutide, and we won’t until it clears FDA review and there’s a legitimate, medically supervised way to prescribe it. Our providers are tracking the trial data closely. In the meantime, if the results retatrutide is producing in trials caught your attention, semaglutide and tirzepatide protocols are FDA-approved options available today with real safety data behind them.
Explore Weight-Loss Options Available at Dynamis Today
Retatrutide might be worth watching, but it isn’t something you can start today, safely or otherwise. If you’re ready to address weight loss now, our board-certified providers build personalized weight-loss protocols around comprehensive lab work using GLP-1 medications that are already approved, monitored, and backed by years of real-world data.
Your dedicated Personal Health Coach stays involved throughout, so you’re never guessing about what you’re taking or why. If retatrutide becomes a real option at Dynamis down the road, you’ll hear it from us directly, not from an unregulated vendor’s ad.
Frequently Asked Questions
Can you combine retatrutide with other GLP-1 medications?
Retatrutide already activates GLP-1, GIP, and glucagon receptors, so combining it with a separate GLP-1 drug like semaglutide would duplicate a mechanism it already covers. None of Lilly’s TRIUMPH trials study it alongside another incretin medication, and retatrutide isn’t available for prescription yet, so the combination question doesn’t apply in practice today.
How long does 10mg of retatrutide last in the body?
In Phase 2 trials, retatrutide’s half-life measured at roughly 6 days, similar to tirzepatide. A 10mg dose stays active in the body for about 3 to 4 weeks before it’s fully cleared, which is why the trials dose it weekly. This is trial data on an investigational drug, not dosing guidance, since retatrutide isn’t available by prescription yet.
How is retatrutide dosed in clinical trials?
Trial participants start at 2mg once weekly and step up every 4 weeks, moving through 2mg, 4mg, 6mg, and 9mg before reaching the 12mg maintenance dose tested in Phase 3. Full escalation takes about 16 to 20 weeks. This gradual approach reduces gastrointestinal side effects, which is why every TRIUMPH trial now starts participants at the same low dose regardless of their eventual target.
What will retatrutide cost once it’s FDA-approved?
No official price exists yet, since retatrutide hasn’t been approved. Analysts estimate it will likely launch in a range similar to tirzepatide, roughly $1,000 to $1,500 per month before insurance or manufacturer savings programs. Coverage will depend on which condition it’s approved for, since obesity medications aren’t consistently covered even after approval.
Can retatrutide help with type 2 diabetes, not just weight loss?
Yes. In a separate Phase 2 trial in people with type 2 diabetes, retatrutide produced an average 16.9% weight loss over 36 weeks along with improvements in blood sugar control. Lilly is running Phase 3 trials specifically for type 2 diabetes in addition to the obesity-focused TRIUMPH program, since the same three-receptor mechanism affects both conditions.
